- ‘PICoP global‘ – an international collaboration assessing neoepitopes for patient-specific vaccination in Colon and Pankreas Cancer
‘PICoP global‘ – an international collaboration assessing neoepitopes for patient-specific vaccination in Colon and Pankreas Cancer
Are you interested in learning about our current study on developing personalized, immune-based therapy to trigger patients’ own immune responses against tumors?
Watch Dr. Peter Bauer, MD, Chief Scientific Officer at CENTOGENE, as he discusses ‘PICoP global’ – our recently launched two-year global study that may have a considerable impact on cancer immunotherapy and individualized treatment for patients via peptide-based immunization for Colon- and Pancreas-Carcinoma.
• Colon and pancreas cancer in the developing countries
• Cancer immune therapy
• Neoepitopes as targets for patient-specific immune therapy
• Molecular approaches to identify neoepitopes
Dr. Peter Bauer
Dr. Peter Bauer, MD serves as CENTOGENE’s Chief Scientific Officer, where he combines clinical and medical understanding in genetic testing with an excellent knowledge of the latest scientific development ̶, based on his extraordinary experience especially in high-throughput genetic testing using next-generation sequencing.
Dr. Bauer received his board certification in Human Genetics in 2006 and headed the molecular diagnostic laboratory at the Institute of Medical Genetics and Applied Genomics at the University Hospital Tübingen. Moreover, he is Vice President of the German Society of Neurogenetics (DGNG). Peter has authored more than 140 publications in neurogenetics, oncogenetics, cardiogenetics and sequencing technology.